Optimising antimicrobial therapy in diabetic foot infections

Drugs

Volumn 67, Issue 2, 2007, Pages 195-214

  Rao, Nalini ^a,c   Lipsky, Benjamin A ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CADEXOMER IODINE; CEFALEXIN; CEFOXITIN; CEFTRIAXONE; CHLORHEXIDINE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; ERTAPENEM; FOSFOMYCIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; OFLOXACIN; PENICILLIN G; PEXIGANAN ACETATE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; RIFAMPICIN; STREPTOKINASE; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM CULTURE; CHRONIC OSTEOMYELITIS; CLINICAL TRIAL; DEBRIDEMENT; DIABETIC FOOT; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; ENTEROCOCCUS; FOOT ULCER; GRAM POSITIVE BACTERIUM; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; HYPERBARIC OXYGEN; IMPLANTATION; OUTPATIENT CARE; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; REVIEW; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DIABETIC FOOT; DRUG ADMINISTRATION ROUTES; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOMYELITIS; PRACTICE GUIDELINES;

ENTEROCOCCUS; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 33847000211     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767020-00003     Document Type: Review

References (148)

1. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004; 20 (S1): S68-77
2. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 1545-51
3. Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 2002; 66 (9): 1655-62
4. Calhoun JH, Overgaard KA, Stevens CM, et al. Diabetic foot ulcers and infections: current concepts. Adv Skin Wound Care 2002, 5
5. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice: neuropathic diabetic foot ulcers. N Engl J Med 2004; 351 (1): 48-55
6. Wieman TJ. Principles of management: the diabetic foot. Am J Surg 2005; 190 (2): 295-9
7. Jude EB, Unsworth PF. Optimal treatment of infected diabetic foot ulcers. Drugs Aging 2004; 21 (13): 833-50
8. Lipsky BA, Berendt AR, Deery HG, et al. IDSA guidelines: diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910
9. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-4
10. Caputo GM, Cavanagh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994; 331 (13): 854-60
11. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-62
12. Ambrosch A, Lehnert H, Lobmann R. Microbiological aspects and antibiotic therapy of diabetic foot infections. Med Klin (Munich) 2003; 98: 259-65
13. Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med 2002; 34: 419-27
14. Macfarlane RM, Jeffcoate WJ. Factors contributing to the presentation of diabetic foot ulcers. Diabet Med 1997; 14: 867-79
15. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990; 4: 409-32
16. Grayson ML. Diabetic foot infections: antimicrobial therapy. Infect Dis Clin North Am 1995; 9: 143-61
17. Joseph WS, Axler DA. Microbiology and antimicrobial therapy of diabetic foot infections. Clin Podiatr Med Surg 1990; 7: 467-81
18. Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections: bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 1996; 19: 638-41
19. El-Tahawy AT. Bacteriology of diabetic foot. Saudi Med J 2000; 21: 344-7
20. Urbancic-Rovan V, Gubina M. Bacteria in superficial diabetic foot ulcers. Diabet Med 2000; 17: 814-5
21. Sims D, Keating SE, DeVicentis AF. Bacteriology of diabetic foot ulcers. J Foot Surg 1984; 23: 149-51
22. Jones EW, Edwards R, Finch R, et al. A microbiological study of diabetic foot lesions. Diabet Med 1985; 2: 213-5
23. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis 1995; 20 Suppl. 2: S283-8
24. Pathare NA, Bal A, Talvalkar GV, et al. Diabetic foot infections: a study of microorganisms associated with the different Wagner grades. Indian J Pathol Microbiol 1998; 41: 437-41
25. Sapico FL, Witte JL, Canawati HN, et al. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984; 6 Suppl. 1: S171-6
26. Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections: bacteriologic analysis. Arch Intern Med 1986; 146: 1935-40
27. Hunt JA. Foot infections in diabetes are rarely due to a single microorganism. Diabet Med 1992; 9: 749-52
28. Ge Y, MacDonald D, Hait H, et al. Microbiological profile of infected diabetic foot ulcers. Diabet Med 2002; 19: 1032-4
29. Dang CN, Prasad YD, Boulton AJ, et al. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003; 20: 159-61
30. Tentolouris N, Jude EB, Smirnof I, et al. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999 Sep; 16 (9): 767-71
31. Tentolouris N, Petrikkos G, Vallianou N, et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 2006; 12: 186-9
32. Game FL, Boswell T, Soar C, et al. Outcome in diabetic foot ulcers with or without methicillin resistant Staphylococcus aureus (MRSA) [abstract]. Diabet Med 2003; 20 Suppl. 2: 30
33. Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded multicentre trial. Lancet 2005; 366: 1695-703
34. Senior C. Assessment of infection in diabetic foot ulcers. J Woundcare 2000; 9 (7): 313-7
35. Williams DT, Hilton JR, Harding KG. Diagnosing foot infection in diabetes. Clin Inf Dis 2004; 39 (S2): S83-6
36. Lavery LA, Armstrong DG, Wunderlich RP, et al. Risk factors for foot infections in persons with diabetes mellitus. Diabetes Care 2006; 29: 1288-93
37. Wysocki AB. Evaluating and managing open skin wounds: colonization versus infection. AACN Clin Issues 2002; 13: 382-97
38. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18 (5): 683-93
39. Berendt AR, Lipsky B. Is this bone infected or not? Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic food. Curr Diabetes Rep 2004; 4 (6): 424-9
40. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997; 25: 1318-26
41. Snyder RJ, Cohen MM, Sun G, et al. Osteomyelitis in the diabetic patient: diagnosis and treatment. Part 1: overview, diagnosis and microbiology. Ostomy Wound Manage 2001; 47: 24-30
42. Snyder RJ, Cohen MM, Sun C, et al. Osteomyelitis in the diabetic patient: diagnosis and treatment. Part 2: medical, surgical, and alternative treatments. Ostomy Wound Manage 2001; 47: 24-30, 32-41; quiz 43
43. Grayson ML, Gibbons GW, Balogh K, et al. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995; 273: 721-3
44. Shone A, Burnside J, Chipchase S, et al. Probing the validity of the probe-to-bone test in the diagnosis of osteomyelitis of the foot in diabetes. Diabetes Care 2006; 29: 945
45. Lavery LA, Armstrong DG, Peters E, et al. "Probe to bone" for diagnosing diabetic foot osteomyelitis: reliable or relic? Diabetes Care. In press
46. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis. Clin Inf Dis 2006; 42 (1): 57-62
47. Kessler L, Piemont Y, Ortega F, et al. Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabetic Med 2006; 23 (1): 99-102
48. Jacobson AF, Harley JD, Lipsky BA, et al. Diagnosis of osteomyelitis in the presence of soft-tissue infection and radiologic evidence of osseous abnormalities: value of leukocyte scintigraphy. AJR Am J Roentgenol 1991; 157: 807-12
49. Wraight PR, Lawrence SM, Campbell DA, et al. Creation of a multidisciplinary, evidence-based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications. Diabetic Med 2005; 22 (2): 127-36
50. Zgonis T, Roukis TS. A systematic approach to diabetic foot infections. Adv Ther 2005; 22 (3): 244-62
51. Frykberg RG. A summary of guideline for managing the diabetic foot. Adv Skin Wound Care 2005; 18 (4): 209-14
52. EIdor R, Raz I, Ben Yahuda A, et al. New and experimental approaches to treatment of diabetic foot ulcers: a comprehesive review of emerging treatment strategies. Diabetic Med 2004; 21 (11): 1161-73
53. Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol Ther 2004; 6 (2): 167-77
54. Cavanagh PR, Lipsky BA, Bradbury AW, et al. Treatment of diabetic foot ulcers. Lancet 2005; 366 (9498): 1725-35
55. Lipsky BA, Berendt AR, Embil J, et al. Diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 2004; 20 Suppl. 1: S56-64
56. Lipsky BA, Berendt AR. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev 2000; 16 Suppl. 1: S42-6
57. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004; 39 (S2): S104-14
58. International Working Group on the Diabetic Foot. International consensus on the diabetic foot [CD-ROM]. Brussels: International Diabetes Foundation, 2003 May
59. Berendt AR, Lipsky BA. Should antibiotics be used in the treatment of the diabetic foot? Diabetic Foot 2003; 6: 18-28
60. Hartemann-Heurtier A, Marty L, Ha Van G, et al. Role of antibiotic therapy in diabetic foot management [in French]. Diabetes Metab 2000; 26: 219-24
61. Nelson EA, O'Meara S, Golder S, et al. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabetic Med 2006; 23 (4): 348-59
62. Nelson EA, O'Meara S, Craig D, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess 2006; 10: 1-238
63. Zgonis T, Jolly GP, Buren BJ, et al. Diabetic foot infections and antibiotic therapy. Clin Podiatr Med Surg 2003; 20: 655-69
64. Edmonds M. Infection in the neuroischemic foot. Int J Lower Ext Wounds 2005; 4 (3): 145-53
65. Kingsley A. The wound infection continuum and its application to clinical practice. Ostomy Wound Manage 2003 Jul; 49 (7A Suppl.): 1-7
66. Edmonds M, Foster A. The use of antibiotics in the diabetic foot. Am J Surg 2004; 187 (5A): 25-8S
67. Edwards R, Harding KG. Bacteria and wound healing. Curr Opin Infect Dis 2004; 17: 91-6
68. Chantelau E, Tanudjaja T, Altenhofer F, et al. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 1996; 13: 156-9
69. Apelqvist J, Ragnarson-Tennvall G, Larsson J. Topical treatment of diabetic foot ulcers: an economic analysis of treatment alternatives and strategies. Diabet Med 1995; 12: 123-8
70. Coutts P, Sibbald RG. The effect of a silver-containing Hydrofiber dressing on superficial wound bed and bacterial balance of chronic wounds. Int Wound J 2005; 2 (4): 348-56
71. O'Meara SM, Cullum NA, Majid M, et al. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg 2001; 88: 4-21
72. Vandeputte J, Grayson L. Clinical trial on the control of diabetic foot infection by an immunomodulating hydrogel containing 65% glycerin. 6th European Conference on Advances in Wound Management. London: Macmillan Magazines, 1997: 50-3
73. Markevich YO, McLeod-Roberts J, Mousley M, et al. Maggot therapy for diabetic neuropathic foot wounds [abstract no. 59]. Proceedings of the 36th Annual Meeting of the European Association for the Study of Diabetes; 2000 Sep 17-21; Jerusalem, Israel. Diabetologia 2000; 43 Suppl. 1: A15
74. Lipsky BA, McDonald D, Litka P. Treatment of infected diabetic foot ulcers: topical MSI-78 vs oral ofloxacin. Diabetologia 1997; 40: 482
75. Caravaggi C, De Giglio R, Pritelli C, et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of non-infected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care 2003; 26 (10): 2853-9
76. Yamaguchi Y, Yoshida S, Sumikawa Y, et al. Rapid healing of intractable diabetic foot ulcers with exposed bones following a novel therapy of exposing bone marrow cells and then grafting epidermal sheets. Br J Dermatol 2004; 151 (5): 1019-28
77. Marchina MD, Renzi G. A new antiseptic preparation used for the disinfection of cutaneous dystrophic ulcers [in Italian]. Chronica Dermatologica 1997; 7: 873-85
78. Rhaiem BB, Ftouhi B, Brahim SB, et al. A comparative study of saccharose use in the treatment of cutaneous lesions in diabetic patients: about 80 cases [in French]. Tunisie Med 1998; 76: 19-23
79. Peterson LR, Lissack LM, Canter K, et al. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med 1989; 86: 801-8
80. Lipsky BA, Pecoraro RE, Larson SA, et al. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990; 150: 790-7
81. Gerards V, Schiewe U, Gerards HH, et al. Amoxicillin/clavulanic acid in therapy of bacterial infections of the diabetic foot: results of an observational study. MMW Fortschr Med 2000; 142: 187-94
82. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampicinofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001; 48 (6): 927-30
83. Bouter KP, Visseren FLJ, Van Loenhour RMM, et al. Treatment of diabetic foot infection: an open randomized comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy. Int J Antimicrobial Agents 1996; 7: 143-7
84. Erstad BI. Jr, McIntyre Jr KE, Mills JL. Prospective, randomized comparison of ampicillin/sulbactam and cefoxitin for diabetic foot infections. Vascular Surg 1997; 31: 419-26
85. Graham DR, Talan DA, Nichols RI, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35: 381-9
86. Marvaso A, Esposito S, Noviello S, et al. Outpatient parenteral antibiotic therapy (OPAT) of diabetic foot infections with piperacillin/ tazobactam. Infect Med 2002; 10: 230-5
87. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate: Linezolid Diabetic Foot Infections Study Group. Clin Infect Dis 2004; 38: 17-24
88. Clay PG, Graham MR, Lindsey CC, et al. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. Am J Geriatr Pharmacother 2004; 2: 181-219
89. Lobmann R, Ambrosch A, Seewald M, et al. Antibiotic therapy for diabetic foot infections: comparison of cephalosporins with chinolones. Diabetes Nutr Metab 2004; 17: 156-62
90. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers; evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semisynthetic penicillin for complicated skin and skin-structure infections. J Antimicrob Chemother 2005; 55: 240-5
91. Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect 2005; 6 (1): 27-40
92. Stengel D, Gorzer E, Schintler M, et al. Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J Chemother 2005; 17 (5): 527-35
93. Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg 2000; 39: 124-30
94. Armstrong DG, Findlow AH, Oylbo SO, et al. The use of absorbable antibiotic-impregnated calcium sulphate pellets in the management of diabetic foot infections. Diabet Med 2001; 18: 942-3
95. Frykberg RG. An evidence-based approach to diabetic foot infections. Am J Surg 2003; 186 (5A): 44-54S; 64S
96. Hunt D. Using evidence in practice: foot care in diabetes. Endocrinol Metab Clin North Am 2002; 31 (3): 603-11
97. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999; 26: 267-76
98. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352 (14): 1436-44
99. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003; 51 (5): 1261-8
100. Bernard L, El-Hajj I, Pron B, et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis. J Clin Pharm Ther 2001; 26 (6): 445-51
101. Guglielimo BJ, Luber AD, Paletta Jr D, et al. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 2000; 1: 205-7
102. Cunha BA. Antibiotic selection for diabetic foot infections. J Foot Ankle Surg 2000, 7
103. Sheppard SJ. Antibiotic treatment of infected diabetic foot ulcers. J Antimicrob Chemother 2005; 14 (6): 260-3
104. Rao N. Anti-infective therapy for foot ulcers in patients with diabetes. Clin Orthop Res 2005; 439: 87-90
105. Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin Pharmacother 2005; 6: 263-73
106. West NJ. Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health Syst Pharm 1995; 52: 1199-207; quiz 1240
107. Johns Hopkins Division of Infectious Diseases. Johns Hopkins antibiotic guide [online]. Available from URL: http://www.hopkins-abxguide.org/main.cfm [Accessed 2006 Dec 19]
108. Tan JS, Friedman NM, Hazelton-Miller C, et al. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputations? Clin Infect Dis 1996; 23: 286-91
109. Armstrong DG, Lavery LA, Nixon BP, et al. It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound. Clin Inf Dis 2004; 39 (S2): S92-9
110. Henke PK, Blackburn SA, Wainess RW. Osteomyelitis of the foot and toe in adults is a surgical disease. Ann Surg 2005; 241 (6): 885-94
111. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis 2004; 39 (S2): S115-22
112. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9 (3): 127-38
113. Millington JT, Norris TW. Effective treatment strategies for diabetic foot wounds. J Fam Pract 2000; 49 (11 Suppl.): S40-8
114. Wright JB, Lam K, Hansen D, et al. Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control 1999; 27: 344-50
115. Mayer DA, Tsapogas MJ. Povidone-iodine and wound healing: a critical review. Wounds 1993; 5: 14-23
116. Mumcuoglu KY. Clinical applications for maggots in wound care. Am J Clin Dermatol 2001; 2: 219-27
117. Rayman A, Stansfield G, Woollard T, et al. Use of larvae in the treatment of diabetic necrotic foot. Diabetic Foot 1998; 1: 7-13
118. Claxton MJ, Armstrong DG, Short B, et al. 5 Questions-and answers-about maggot debridement therapy. Adv Skin Wound Care 2003; 16: 99-102
119. Armstrong DG, Salas P, Short B, et al. Maggot therapy in "lower extremity hospice" wound care: fewer amputations and more antibiotic-free days. J Am Podiatr Med Assoc 2005; 95 (3): 254-7
120. Sherman RA, Shimoda KJ. Presurgical maggot debridement of soft tissue wounds is associated with decreased rates of postoperative infection. Clin Infect Dis 2004; 39 (7): 1067-70
121. Espensen EH, Nixon BP, Lavery LA, et al. Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds. J Am Podiatr Med Assoc 2002; 92: 395-7
122. Joseph E, Hamori CA, Bergman S, et al. A prospective, randomized trial of vacuum-assisted closure versus standard therapy of chronic non-healing wounds. Wounds 2000; 12: 60-7
123. McCallon SK, Knight CA, Valiulus JP, et al. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage 2000; 46: 28-32, 34
124. Armstrong DG, Lavery LA, Abu-Rumman P, et al. Outcomes of subatmospheric pressure dressing therapy on wounds of diabetic foot. Ostomy Wound Manage 2002; 48: 64-8
125. Nagai MD, Embil JM. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2002; 2: 211-8
126. Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel: Becaplermin Studies Group. Am J Surg 1998, 73S
127. Steed DL. Growth factors in the treatment of diabetic foot ulcers. Wounds 1993; 5: 80-3
128. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in wound healing. Am J Surg 1998; 176: 80A-2S
129. Williams RL, Armstrong DG. Wound healing: new modalities for a new millennium. Clin Podiatr Med Surg 1998; 15: 117-28
130. Embil JM, Papp K, Sibbald G, et al. Recombinant human platelet-derived growth factor -BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Reagen 2000; 8: 162-8
131. Knighton DR, Fiegel VD. Growth factors and comprehensive surgical care of diabetic wounds (review). Curr Opin Gen Surg 1993, 9
132. Edmonds M, Bates M, Doxford M, et al. New treatments in ulcers healing and wound infection. Diabetes Metab Res Rev 2000; 16 Suppl. 1: S51-4
133. Browne AC, Vearncombe M, Sibbald RG. High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of dermagraft. Ostomy Wound Manage 2001; 47: 44-9
134. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neutropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24: 290-5
135. Peck KR, Son DW, Song JH, et al. Enhanced neutrophil functions by recombinant human granulocyte colony stimulating factors in diabetic patients with foot infections in vitro. J Korean Med Sci 2001; 16: 39-44
136. Gough A, Clapperton M, Rolando N, et al. Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350 (9081): 855-9
137. de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrobial Agents Chemother 2001; 45: 1094-8
138. Yonem A, Cakir B, Guler S, et al. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3: 332-7
139. Kastenbauer T, Hornlein B, Sokol G, et al. Evaluation of granulocyte-colony stimulating factor (filgrastim) in infected diabetic foot ulcers. Diabetologia 2003; 46 (1): 27-30
140. Viswanathan V, Mahesh U, Jayaraman M, et al. Beneficial role of granulocyte colony-stimulating factor in foot infection in diabetic patients. J Assoc Physicians India 2003; 51: 90-1
141. Cruciani M, Lipsky BA, Mengoli C, et al. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis. Diabetes Care 2005; 28 (2): 454-60
142. Bakker DJ. Hyperbaric oxygen therapy and the diabetic foot. Diabetes Metab Res Rev 2000; 16 (S1): S55-8
143. Kalani M, Jorneskog G, Naderi N, et al. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers: long-term follow-up. J Diabetes Complications 2002; 16: 153-8
144. Wunderlich RP, Peters EJ, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care 2000; 23: 1551-5
145. Wang C, Schwaitzbert S, Berliner E, et al. Hyperbaric oxygen for treating wounds: a systematic review of the literature. Arch Surg 2003; 138: 272-9; discussion 280
146. Lee SS, Chen CY, Chan YS, et al. Hyperbaric oxygen in the treatment of diabetic foot infection. Changgeng Yi Xue Za Zhi 1997; 20: 17-22
147. Kranke P, Bennette M, Roeckl-Wiedmann I, et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2004; (2): CD004123
148. Barnes RC. Point: Hyperbaric oxygen is beneficial for diabetic foot wounds. Clin Infect Dis 2006; 43 (2): 188-92 149. Berendt AR. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin Infect Dis 2006; 43 (2): 193-8